TY - JOUR
T1 - Newer-generation ventricular assist devices
AU - Agarwal, Shvetank
AU - High, Kane M.
N1 - Funding Information:
Several pumps are currently being developed around the world incorporating either magnetic or hydrodynamic levitation or a combination of both. These include, the Arrow CorAide™ (Arrow International Inc., Reading, PA, USA in collaboration with the Cleveland Clinic Foundation) 44 ; the Heartmate III ® (Thoratec Corporation, Pleasanton, CA, USA, in collaboration with and Levitronix GmbH, Zurich, Switzerland) 45 ; the Ibaraki University Pump, (Hitachi, Japan) 46 ; the MiTi Heart ® (MiTiHeart Corporation, Gaithersburg, MD) 47 ; the TMDU/TIT LVAS (co-developed by the Tokyo Medical and Dental University and the Tokyo Institute of Technology); and the Magnevad II ® (Gold Medical Technologies, Inc., Valhalla, NY, USA). 48
PY - 2012/6
Y1 - 2012/6
N2 - The latest generation of ventricular assist devices has evolved from the pulsatile, volume-displacement pumps of the 1990s to today's non-pulsatile, constant pressure-generating rotary pumps. These pumps include both centrifugal and axial flow devices that are currently being used or are in advanced development. Rotary pumps have the advantage of a much longer and more reliable duty life than pulsatile pumps. They are also considerably smaller than pulsatile pumps, requiring less invasive surgery for implantation and smaller transcutaneous (electrical rather than pneumatic) drivelines. Most of these devices have been approved as a bridge to transplant (BTT) while some are currently in trials for destination therapy (DT) in Europe (Conformité Européenne (CE) mark) or the United States (Food and Drug Administration (FDA)). This article discusses the current generation of pumps, examining particular design features as highlighted by the designers as well as the current approval status of each device in the United States and Europe.
AB - The latest generation of ventricular assist devices has evolved from the pulsatile, volume-displacement pumps of the 1990s to today's non-pulsatile, constant pressure-generating rotary pumps. These pumps include both centrifugal and axial flow devices that are currently being used or are in advanced development. Rotary pumps have the advantage of a much longer and more reliable duty life than pulsatile pumps. They are also considerably smaller than pulsatile pumps, requiring less invasive surgery for implantation and smaller transcutaneous (electrical rather than pneumatic) drivelines. Most of these devices have been approved as a bridge to transplant (BTT) while some are currently in trials for destination therapy (DT) in Europe (Conformité Européenne (CE) mark) or the United States (Food and Drug Administration (FDA)). This article discusses the current generation of pumps, examining particular design features as highlighted by the designers as well as the current approval status of each device in the United States and Europe.
UR - http://www.scopus.com/inward/record.url?scp=84865243077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865243077&partnerID=8YFLogxK
U2 - 10.1016/j.bpa.2012.01.003
DO - 10.1016/j.bpa.2012.01.003
M3 - Review article
C2 - 22910085
AN - SCOPUS:84865243077
VL - 26
SP - 117
EP - 130
JO - Best Practice and Research: Clinical Anaesthesiology
JF - Best Practice and Research: Clinical Anaesthesiology
SN - 1521-6896
IS - 2
ER -